Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S5.62
P/E—
Fwd P/E16.54
PEG2.06
52W— – —
RSI—
Target$357.03 (-7.9%)
Beta0.40
Div2.46%
Loading chart…
RSI (14)
Loading patterns…
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 67
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
3Bullish
0Bearish
0Neutral
▲ Double Bottom — Two lows ~$319.55 — bullish reversal confirmed
▲ Double Bottom — Two lows ~$328.18 — bullish reversal confirmed
▲ Bull Flag — Breakout after +9% pole — bullish continuation
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
88%
7/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$357.03
-7.9% upside
Low $215
—
High $427
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| Barclays | Equal-Weight | — | ↔ Maintain | 2026-07-29 |
| UBS | Buy | — | ↔ Maintain | 2026-07-13 |
| Guggenheim | Neutral | — | ↔ Maintain | 2026-07-13 |
| Morgan Stanley | Equal-Weight | — | ↔ Maintain | 2026-07-08 |
| Truist Securities | Hold | — | ↔ Maintain | 2026-07-07 |
| Cantor Fitzgerald | Neutral | — | ↔ Reiterate | 2026-07-06 |
| Mizuho | Neutral | — | ↔ Maintain | 2026-06-16 |
| Piper Sandler | Overweight | — | ↔ Maintain | 2026-05-14 |
| Canaccord Genuity | Hold | — | ● Initiate | 2026-04-21 |
| Jefferies | Hold | — | ● Initiate | 2026-03-10 |
| Wells Fargo | Equal-Weight | — | ↔ Maintain | 2026-02-19 |
| Freedom Broker | Hold | Buy → Hold | ▼ Downgrade | 2026-02-12 |
| Argus Research | Buy | — | ↔ Maintain | 2026-02-06 |
| Citigroup | Neutral | — | ↔ Maintain | 2026-02-04 |
| Leerink Partners | Outperform | — | ↔ Maintain | 2026-02-04 |
| Bernstein | Market Perform | Outperform → Market Perform | ▼ Downgrade | 2026-01-20 |
| BMO Capital | Outperform | — | ↔ Maintain | 2025-12-03 |
Barclays
2026-07-29
Equal-Weight
↔ Maintain
UBS
2026-07-13
Buy
↔ Maintain
Guggenheim
2026-07-13
Neutral
↔ Maintain
Morgan Stanley
2026-07-08
Equal-Weight
↔ Maintain
Truist Securities
2026-07-07
Hold
↔ Maintain
Cantor Fitzgerald
2026-07-06
Neutral
↔ Reiterate
Mizuho
2026-06-16
Neutral
↔ Maintain
Piper Sandler
2026-05-14
Overweight
↔ Maintain
Canaccord Genuity
2026-04-21
Hold
● Initiate
Jefferies
2026-03-10
Hold
● Initiate
Wells Fargo
2026-02-19
Equal-Weight
↔ Maintain
Freedom Broker
2026-02-12
Hold
(from Buy)
▼ Downgrade
Argus Research
2026-02-06
Buy
↔ Maintain
Citigroup
2026-02-04
Neutral
↔ Maintain
Leerink Partners
2026-02-04
Outperform
↔ Maintain
Bernstein
2026-01-20
Market Perform
(from Outperform)
▼ Downgrade
BMO Capital
2025-12-03
Outperform
↔ Maintain
Profitability
Gross Margin
71.44%TTM
Op. Margin
33.80%TTM
ROE
101.32%TTM
Rev. Growth
5.80%YoY
Free Cash Flow
7.44BTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
623.75MRQ
Current Ratio
1.26MRQ
Cash
12.04BMRQ
Total Debt
57.32BMRQ
Net Debt
—MRQ
Income
Div. Yield
2.46%TTM
Annual Rate
10.08Fwd
Payout Ratio
67.22%TTM
Dividend History
Payout Ratio (TTM): 67.22%
| Date | Amount / Share | Yield at Payment |
|---|---|---|
| 2026-05-15 | $2.5200 | 0.77% |
| 2026-02-13 | $2.5200 | 0.69% |
| 2025-11-21 | $2.3800 | 0.71% |
| 2025-08-22 | $2.3800 | 0.83% |
| 2025-05-16 | $2.3800 | 0.90% |
| 2025-02-14 | $2.3800 | 0.85% |
| 2024-11-18 | $2.2500 | 0.85% |
| 2024-08-16 | $2.2500 | 0.74% |
| 2024-05-16 | $2.2500 | 0.76% |
| 2024-02-15 | $2.2500 | 0.83% |
| 2023-11-16 | $2.1300 | 0.85% |
| 2023-08-17 | $2.1300 | 0.88% |
| 2023-05-17 | $2.1300 | 1.04% |
| 2023-02-14 | $2.1300 | 0.98% |
| 2022-11-16 | $1.9400 | 0.76% |
| 2022-08-17 | $1.9400 | 0.87% |
| 2022-05-16 | $1.9400 | 0.90% |
| 2022-02-14 | $1.9400 | 0.99% |
| 2021-11-15 | $1.7600 | 0.98% |
| 2021-08-16 | $1.7600 | 0.89% |
| 2021-05-14 | $1.7600 | 0.82% |
| 2021-02-11 | $1.7600 | 0.88% |
| 2020-11-13 | $1.6000 | 0.80% |
| 2020-08-14 | $1.6000 | 0.80% |
| 2020-05-15 | $1.6000 | 0.80% |
| 2020-02-13 | $1.6000 | 0.87% |
| 2019-11-14 | $1.4500 | 0.81% |
| 2019-08-14 | $1.4500 | 0.90% |
| 2019-05-16 | $1.4500 | 1.06% |
| 2019-02-14 | $1.4500 | 0.97% |
| 2018-11-15 | $1.3200 | 0.86% |
| 2018-08-16 | $1.3200 | 0.85% |
| 2018-05-16 | $1.3200 | 0.97% |
| 2018-02-14 | $1.3200 | 0.94% |
| 2017-11-16 | $1.1500 | 0.87% |
| 2017-08-15 | $1.1500 | 0.88% |
| 2017-05-15 | $1.1500 | 0.94% |
| 2017-02-13 | $1.1500 | 0.91% |
| 2016-11-14 | $1.0000 | 0.91% |
| 2016-08-15 | $1.0000 | 0.77% |
How AMGN Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 209.21B |
| Enterprise Value | 254.38B |
| Trailing P/E | 26.94 |
| Forward P/E | 16.54 |
| PEG Ratio (5yr) | 2.06 |
| Price/Sales (ttm) | 5.62 |
| Price/Book (mrq) | 22.76 |
| EV/Revenue | 6.83 |
| EV/EBITDA | 15.04 |
Share Statistics
| Avg Vol (3m) | 2.74M |
| Shares Outstanding | 539.71M |
| Float | 538.22M |
| % Held by Insiders | 0.22% |
| % Held by Institutions | 85.01% |
| Short Ratio | 4.66 |
| Short % of Float | 2.38% |
Profitability
| Gross Margin | 71.44% |
| Operating Margin (ttm) | 33.80% |
| Profit Margin | 20.96% |
| Return on Assets (ttm) | 8.35% |
| Return on Equity (ttm) | 101.32% |
Income Statement
| Revenue (ttm) | 37.22B |
| Revenue Growth (yoy) | 5.80% |
| Gross Profit (ttm) | 26.59B |
| EBITDA | 16.92B |
| Net Income (ttm) | 7.80B |
| Diluted EPS (ttm) | 14.39 |
| EPS Growth (yoy) | 4.40% |
Balance Sheet
| Total Cash (mrq) | 12.04B |
| Total Debt (mrq) | 57.32B |
| Debt / Equity (mrq) | 623.75 |
| Current Ratio (mrq) | 1.26 |
| Book Value / Share | 17.03 |
| Operating CF (ttm) | 10.76B |
| Free Cash Flow (ttm) | 7.44B |
Trading & Dividends
| Beta (5Y) | 0.40 |
| 50-Day MA | 352.16 |
| 200-Day MA | 342.42 |
| Fwd Dividend Yield | 256.00% |
| Payout Ratio | 67.22% |
Ownership Breakdown
Institutional 85.01%
Insider 0.22%
Public 14.8%
Short Interest
2.38% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in AMGN in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-19 | KLOTMAN MARY E | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | GARLAND GREGORY C. | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | ISHRAK OMAR SYED | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | JACKS TYLER | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | AUSTIN WANDA M | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | DRUKER BRIAN J | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | DRAKE MICHAEL V | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | HOLLEY CHARLES M JR | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | KULLMAN ELLEN JAMISON | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | ECKERT ROBERT ANDREW | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-19 | MILES AMY E | Director | Stock Award(Grant) at price 0.00 per share. | 665 | — |
| 2026-05-05 | BUSCH MATTHEW C. | Officer | Stock Award(Grant) at price 0.00 per share. | 455 | — |
| 2026-05-05 | ISHRAK OMAR SYED | Director | Stock Award(Grant) at price 0.00 per share. | 106 | — |
| 2026-05-05 | GORDON MURDO | Officer | Stock Award(Grant) at price 0.00 per share. | 3,640 | — |
| 2026-05-05 | GRIFFITH PETER H. | Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 3,640 | — |
| 2026-05-05 | REESE DAVID M. | Chief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 2,912 | — |
| 2026-05-05 | KHOSLA RACHNA | Officer | Stock Award(Grant) at price 0.00 per share. | 500 | — |
| 2026-05-05 | MILLER DEREK | Officer | Stock Award(Grant) at price 0.00 per share. | 910 | — |
| 2026-05-05 | DRAKE MICHAEL V | Director | Stock Award(Grant) at price 0.00 per share. | 79 | — |
| 2026-05-05 | BRADNER JAMES E. | Officer | Stock Award(Grant) at price 0.00 per share. | 3,337 | — |
| 2026-05-05 | GRYGIEL NANCY A | Officer | Stock Award(Grant) at price 0.00 per share. | 485 | — |
| 2026-05-05 | SANTOS ESTEBAN | Officer | Stock Award(Grant) at price 0.00 per share. | 2,730 | — |
| 2026-05-05 | BRADWAY ROBERT A | Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 12,136 | — |
| 2026-05-05 | HOLLEY CHARLES M JR | Director | Stock Award(Grant) at price 0.00 per share. | 128 | — |
| 2026-05-05 | GRAHAM JONATHAN P | General Counsel | Stock Award(Grant) at price 0.00 per share. | 2,609 | — |
KLOTMAN MARY E
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
GARLAND GREGORY C.
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
ISHRAK OMAR SYED
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
JACKS TYLER
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
AUSTIN WANDA M
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
DRUKER BRIAN J
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
DRAKE MICHAEL V
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
HOLLEY CHARLES M JR
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
KULLMAN ELLEN JAMISON
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
ECKERT ROBERT ANDREW
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
MILES AMY E
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-19
665 sh
—
BUSCH MATTHEW C.
Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
455 sh
—
ISHRAK OMAR SYED
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-05
106 sh
—
GORDON MURDO
Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
3,640 sh
—
GRIFFITH PETER H.
Chief Financial Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
3,640 sh
—
REESE DAVID M.
Chief Technology Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
2,912 sh
—
KHOSLA RACHNA
Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
500 sh
—
MILLER DEREK
Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
910 sh
—
DRAKE MICHAEL V
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-05
79 sh
—
BRADNER JAMES E.
Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
3,337 sh
—
GRYGIEL NANCY A
Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
485 sh
—
SANTOS ESTEBAN
Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
2,730 sh
—
BRADWAY ROBERT A
Chief Executive Officer
Stock Award(Grant) at price 0.00 per share.
2026-05-05
12,136 sh
—
HOLLEY CHARLES M JR
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-05
128 sh
—
GRAHAM JONATHAN P
General Counsel
Stock Award(Grant) at price 0.00 per share.
2026-05-05
2,609 sh
—